Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Average (2016 - 2021)

Historic Equity Average for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Equity Average rose 6051.36% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 6051.36%. This contributed to the annual value of $881.6 million for FY2020, which is 5774.85% up from last year.
  • As of Q3 2021, Neurocrine Biosciences' Equity Average stood at $1.3 billion, which was up 6051.36% from $1.2 billion recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Equity Average peaked at $1.3 billion during Q3 2021, and registered a low of $281.0 million during Q1 2017.
  • For the 5-year period, Neurocrine Biosciences' Equity Average averaged around $624.4 million, with its median value being $464.1 million (2018).
  • Per our database at Business Quant, Neurocrine Biosciences' Equity Average crashed by 3288.64% in 2017 and then surged by 7437.93% in 2021.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Equity Average stood at $359.8 million in 2017, then rose by 28.99% to $464.1 million in 2018, then soared by 30.5% to $605.7 million in 2019, then skyrocketed by 59.36% to $965.2 million in 2020, then surged by 35.99% to $1.3 billion in 2021.
  • Its Equity Average was $1.3 billion in Q3 2021, compared to $1.2 billion in Q2 2021 and $1.2 billion in Q1 2021.